<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963076</url>
  </required_header>
  <id_info>
    <org_study_id>Puressentiel</org_study_id>
    <nct_id>NCT03963076</nct_id>
  </id_info>
  <brief_title>Efficacy of Nasal Spray Hypertonic Puressentiel on Symptoms of Allergic Rhinitis</brief_title>
  <acronym>ENAPAR</acronym>
  <official_title>Evaluation of the Efficiency of Nasal Spray Hypertonic Puressentiel on Symptoms of Patients With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puressentiel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puressentiel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicentric study.

      60 subjects with allergic rhinitis will be enrolled to test the efficacy of nasal hypertonic
      spray Puressentiel on symptoms of allergic rhinitis and nasal peak flow.

      Subjects with allergic rhinitis and nasal obstruction will use during 30 days the nasal spray
      (2 nebulisations /day in each nostril) during 30 days.

      Rhinitis symptoms questionnaire and nasal inspiratory peak flow will be evaluated before and
      after 30 days of exposure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: evaluate the efficiency of a nasal hypertonic spray Puressentiel in subjects with
      allergic rhinitis and nasal obstruction.

      Inclusion criteria: subjects with allergic obstructive rhinitis without treatment or
      remaining symptomatic despite treatment.

      Duration of exposure: 2 nasal sprays per day (morning and evening) during 30 months.

      Primary criteria of efficacy: Rhinitis questionnaire.

      Secondary criteria: Inspiratory nasal peak flow
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective multicentric study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rhinitis auto questionnaire symptoms</measure>
    <time_frame>Measurement at Day 0</time_frame>
    <description>5 questions quoted from 1 (worse) to 5 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rhinitis auto questionnaire symptoms</measure>
    <time_frame>Measurement at Day 30</time_frame>
    <description>5 questions quoted from 1 (worse) to 5 (best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal inspiratory peak flow</measure>
    <time_frame>Measurement at Day 0 and Day 30</time_frame>
    <description>Inspiratory nasal peak flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal inspiratory peak flow</measure>
    <time_frame>Measurement at Day 30</time_frame>
    <description>Inspiratory nasal peak flow</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>allergic rhinitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a nasal hypertonic spray twice a day for one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)</intervention_name>
    <description>One spray of nasal hypertonic spray morning and evening every day during 30 days</description>
    <arm_group_label>allergic rhinitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allergic rhinitis with nasal obstruction

        Exclusion Criteria:

          -  pregnant patients

          -  patients with severe asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>pascal Demoly, MD, PhD</last_name>
    <phone>33675034090</phone>
    <email>pascal.demoly@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Bonnard, PhD</last_name>
    <phone>33180489432</phone>
    <email>c.bonnard@puressentiel.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Caroline Bonnard</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Demoly</last_name>
      <phone>33675034090</phone>
      <email>pascal.demoly@inserm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

